The Wolverine Blend: What’s In It and the Research on Each Component

What is the Wolverine blend?

The Wolverine blend — listed in the catalogue as the “Wolverine Stack” — is the name for a research preparation that supplies two peptides together: BPC-157 and TB-500 (a synthetic peptide based on thymosin β4). That is a naming and composition fact and nothing more: the label tells you which two sequences are in the vial, not that they act together or that the pairing has been studied as a unit. It is one of several multi-peptide research blends in the catalogue.

Because the honest evidence for this preparation is simply the evidence for its two components, the rest of this page does two things: it summarises each component briefly and hands off to that component’s full research page, and it states plainly what the literature does — and does not — say about the two together. Nothing here is a combined-effect claim.

The two components

BPC-157

BPC-157 is a synthetic 15-amino-acid peptide — a pentadecapeptide — corresponding to a fragment of a larger protein identified in gastric juice, first characterised in the research literature in 1993. A defining feature of its literature is that it does not converge on a single receptor: studies describe it as pleiotropic, examining VEGFR2-associated angiogenesis, the nitric-oxide system, ERK1/2 signalling and cytokine modulation in model systems. The evidence is overwhelmingly preclinical — cell and animal models rather than people. For the full mechanism and model detail, see BPC-157 research: mechanism & studies. This is a short neutral summary, not an outcome claim.

TB-500 (thymosin β4)

TB-500 is a synthetic peptide corresponding to the actin-binding region of thymosin β4, a naturally occurring 43-amino-acid peptide. The best-characterised biochemistry is G-actin sequestration — thymosin β4 is described as the principal G-actin–sequestering peptide in mammalian cells, binding monomeric actin and buffering the free-monomer pool (Carlier et al., 1993; Irobi et al., 2004). Beyond that, the literature is pleiotropic and predominantly preclinical. For the full detail, see TB-500 research: thymosin β4 mechanism. Again, a neutral summary of what was studied, not an effect in a reader.

Is there research on the combination itself?

This is the point that matters most for anyone reading about the blend, so it is stated plainly: the published literature studies BPC-157 and TB-500 separately. There is essentially no dedicated, peer-reviewed research on the two administered as a single combination — no controlled study establishing what the pairing does as a unit, and none comparing the combination against either peptide on its own.

Combining the two sequences into one research vial is therefore a formulation and catalogue decision, not a finding. This page makes no claim that the two do anything together, and no claim that a combination is preferable to either component. The two component pages above are the actual evidence base — and each of them is, on its own terms, largely preclinical. Read the blend as a packaging fact and the component pages as the research.

It is worth being explicit about why the honest answer is “essentially none” rather than simply “we have not summarised it here.” Peptide research blends are assembled at the catalogue and formulation stage, whereas the peer-reviewed literature is built around single, defined molecules studied in isolation so that any observed effect can be attributed to one compound. A study of two peptides given together would be a distinct piece of work with its own controls, and for the BPC-157 and TB-500 pairing that work has not been published in any form this page could responsibly cite. The most accurate thing that can be said is what the two component summaries above already establish — each molecule has its own separate, and largely preclinical, record.

Blend vs separate — a formulation fact

The catalogue lists Wolverine at two research sizes — 10 mg and 20 mg — supplied as a co-formulated blend of the two peptides. That is a packaging and formulation description: one vial containing both sequences, characterised as such. The milligram figure on the label is a catalogue quantity that identifies the material, not a dose or a protocol, and this page gives no per-use amount, ratio-as-regimen, or timing. Those transactional details are not the subject here; identity and composition are.

Research-grade sourcing and verification

For laboratory research use only, the Wolverine preparation is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation. For a multi-peptide preparation, identity confirmation of each sequence is the whole assurance — it is what tells a researcher the vial contains what the label says. Check the exact batch on the self-serve verify tool, and see how to read a COA for what the certificate reports. Sourcing and quality-assurance framing only.

Frequently asked questions

Literature cited

1. Chang C-H, et al. “The promoting effect of pentadecapeptide BPC 157 on tendon fibroblasts.” 2011 (PMC6271067). (BPC-157 component.)
2. Vasireddi N, et al. “Systematic review of BPC-157 in orthopaedic sports medicine.” 2025. (BPC-157 component.)
3. Carlier MF, Jean C, Rieger KJ, Lenfant M, Pantaloni D. “Modulation of the interaction between G-actin and thymosin β4 by the ATP/ADP ratio.” PNAS. 1993;90(11):5034–5038. (TB-500 component.)
4. Irobi E, Aguda AH, Larsson M, et al. “Structural basis of actin sequestration by thymosin-β4.” EMBO J. 2004;23(18):3599–3608. (TB-500 component.)
5. “Thymosin beta-4 and TB-500 in tissue healing, regeneration, and musculoskeletal repair: a scoping review.” Applied Sciences. 2026. (TB-500 component.)